Amit Kumar Acquires 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were purchased at an average price of $2.76 per share, for a total transaction of $13,800.00. Following the purchase, the chief executive officer owned 662,000 shares in the company, valued at $1,827,120. This trade represents a 0.76% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Amit Kumar also recently made the following trade(s):

• On Friday, July 31st, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.47 per share, with a total value of $17,350.00.
• On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.04 per share, for a total transaction of $15,200.00.

Anixa Biosciences Stock Performance

Shares of Anixa Biosciences stock opened at $2.76 on Friday. The company has a market capitalization of $95.94 million, a P/E ratio of -8.62 and a beta of 0.51. The company has a fifty day moving average of $3.33 and a 200 day moving average of $2.98. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). Analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIX. BlackRock Inc. purchased a new position in Anixa Biosciences during the second quarter worth $559,000. AXQ Capital LP purchased a new stake in shares of Anixa Biosciences in the second quarter valued at $41,000. Corient Private Wealth LP bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $105,000. Canada Pension Plan Investment Board bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $38,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $29,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ANIX has been the topic of a number of research analyst reports. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Anixa Biosciences currently has a consensus rating of “Hold” and an average price target of $10.00.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.